Supplementary Figure 2:
Bar plot presentation of global depletion of sgRNAs. For each gene, we calculated the number of sgRNAs that could be detected in "Day 0" and control samples of both in vivo and in vitro experiment. Next we counted the number of genes that are targeted by the indicated number of sgRNAs (x-axis) in each experiments. Y-axis (bar height) represents fold change in a number of genes targeted by a given number of sgRNAs compared to Day 0. Positive FC value indicates that the total number sgRNAs targeting a gene is generally depleted both in vitro and in vivo screening. The figure highlights that at each cut off value, more sgRNAs are depleted in in vivo settings compared to in vitro setting.
Supplementary Figure 3:
Comparative analysis of in vitro and in vivo screens. a Each dot represents ratio of a number of sgRNAs (with more than 3 counts) between in vitro and in vivo screens for a single gene. Genes are ordered alphabetically. Enrichment score of 1 indicate no change between the number sgRNAs for a given gene in in vitro and in vivo screening. Most genes have in vitro/in vivo score of more than 1, indicating that sgRNAs are globally depleted/underrepresented in vivo. The genes that seem to more dramatically depleted in vivo are named. b The figure presented in A is ranked ordered to highlight that the enrichment score for most genes is above 1, which is displayed as dotted line.
Supplementary Figure 4:
Comparative analysis of CRISPR viability scores for in vivo and in vitro control experiments. Central panel (scatter plot) presents CRISPR z-scores (control treatment relative to "day 0") for in vitro (y axis) and in vitro (x axis) screens. Side panels present kernel density estimation of corresponding z-score, which indicate that in vivo screening is associated with wider zscore distributions compared to in vitro screening. The lower guardant of the figure highlights the genes depleted both in vitro and in vivo control samples. The genes, which are previously identified as essential fitness genes by Hart et al., (Cell, 2015; PMID: 26627737) are displayed as red dots. Tart et al identified approximately 1600 genes, which is ~8 % of the genome. Among the ~4000 genes in our screening, which are enriched for important transcription factors and epigenetic regulators, ~15% of them are the essential fitness genes (2X enrichment/genome). Notably, among the genes that are commonly depleted both in vitro and in vivo samples, more than 30% are fitness genes, which is 4X enrichment compared to genomic control.
Supplementary Figure 5:
Gene Ontology enrichemnt analysis for top 100 genes depleted in treatment vs control comparison in in vivo and in vitro screening. Number of genes in each category are indicated next the respective bar graphs.
Supplementary Figure 6:
Western blots shows the amount of CENPE and RRM1 protein in control and targeted sgRNAs in two different pancreatic cancer cells by using two best gRNAs according to the CRISPR viability score. β-actin is used as a loading control. 
Supplementary

Supplementary Figure 10:
Receiver operating characteristic curves (ROC) of optimal model (DREBIC, red line) and sub-optimal models. DREBIC is performing better when it constructed from top 225 enriched genes and bottom 175 depleted genes (area under ROC curve is 0.732) than when it is constructed from either of these set of genes. B175 and T225 represent the score when DREBIC is constructed from bottom 175 depleted genes and top 225 enriched genes, respectively. Model established on basal gene expression only (orange) or with all CRISPR scores (black) are only slightly better than random models (one standard deviation from the random models based on permutation analysis), areas under ROCs are 0.458 and 0.643, respectively.
Supplementary Figure 11:
Prediction accuracy of DREBICS components (enriched and depleted genes separately) based on the various numbers of top depleted and enriched genes. The best prediction accuracy is obtained when 225 enriched genes (red dot) and 175 depleted genes (blue dot) are used. 
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